These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

361 related items for PubMed ID: 31155442

  • 21. Current concepts in the treatment of giant cell tumour of bone.
    van der Heijden L, Dijkstra S, van de Sande M, Gelderblom H.
    Curr Opin Oncol; 2020 Jul; 32(4):332-338. PubMed ID: 32541321
    [Abstract] [Full Text] [Related]

  • 22. Outcome of re-operation for local recurrence following pre-operative denosumab administration and curettage for giant cell tumour of bone with difficult joint preservation.
    Tsukamoto S, Hindiskere S, Honoki K, Mavrogenis AF, Tanaka Y, Chinder PS, Donati DM, Errani C.
    Int Orthop; 2023 Jan; 47(1):265-273. PubMed ID: 36282294
    [Abstract] [Full Text] [Related]

  • 23. Denosumab treatment of inoperable or locally advanced giant cell tumor of bone - Multicenter analysis outside clinical trial.
    Rutkowski P, Gaston L, Borkowska A, Stacchiotti S, Gelderblom H, Baldi GG, Palmerini E, Casali P, Gronchi A, Parry M, Campanacci DA, Scoccianti G, Wagrodzki M, Ferrari S, Dijkstra S, Pieńkowski A, Grimer R.
    Eur J Surg Oncol; 2018 Sep; 44(9):1384-1390. PubMed ID: 29650420
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Effect evaluation of denosumab combined with curettage and bone cement reconstruction in the treatment of recurrent giant cell tumor of bone around the knee joint.
    Duan DK, Zhang GC, Sun BJ, Ma TX, Zhao M.
    Eur Rev Med Pharmacol Sci; 2023 Jun; 27(11):5039-5052. PubMed ID: 37318478
    [Abstract] [Full Text] [Related]

  • 27. Prognostic factors for local recurrence in extremity-located giant cell tumours of bone with pathological fracture.
    Medellin MR, Fujiwara T, Tillman RM, Jeys LM, Gregory J, Stevenson JD, Parry M, Abudu A.
    Bone Joint J; 2018 Dec; 100-B(12):1626-1632. PubMed ID: 30499317
    [Abstract] [Full Text] [Related]

  • 28. Evaluation of Local Recurrence in Giant-Cell Tumor of Bone Treated by Neoadjuvant Denosumab.
    Chinder PS, Hindiskere S, Doddarangappa S, Pal U.
    Clin Orthop Surg; 2019 Sep; 11(3):352-360. PubMed ID: 31475058
    [Abstract] [Full Text] [Related]

  • 29. Is a Short-course of Preoperative Denosumab as Effective as Prolonged Therapy for Giant Cell Tumor of Bone?
    Hindiskere S, Errani C, Doddarangappa S, Ramaswamy V, Rai M, Chinder PS.
    Clin Orthop Relat Res; 2020 Nov; 478(11):2522-2533. PubMed ID: 32401001
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Recurrent giant cell tumour of the distal ulna after en bloc resection with preoperative denosumab use.
    Fujihara N, Hamada S, Yoshida M, Tsukushi S.
    BMJ Case Rep; 2021 Nov 11; 14(11):. PubMed ID: 34764115
    [Abstract] [Full Text] [Related]

  • 32. [Denosumab may be a supplement to the surgical treatment of giant cell tumours of bone].
    Sørensen AL, Hansen RL, Jørgensen PH.
    Ugeskr Laeger; 2016 Sep 05; 178(36):. PubMed ID: 27593237
    [Abstract] [Full Text] [Related]

  • 33. Preoperative Denosumab Therapy Against Giant Cell Tumor of Bone is Associated with an Increased Risk of Local Recurrence After Curettage Surgery.
    Asano N, Saito M, Kobayashi E, Morii T, Kikuta K, Watanabe I, Anazawa U, Takeuchi K, Suzuki Y, Susa M, Nishimoto K, Ishii R, Miyazaki N, Mrioka H, Kawai A, Horiuchi K, Nakayama R.
    Ann Surg Oncol; 2022 Jun 05; 29(6):3992-4000. PubMed ID: 35175454
    [Abstract] [Full Text] [Related]

  • 34. Denosumab Does Not Decrease Local Recurrence in Giant Cell Tumor of Bone Treated With En Bloc Resection.
    Tsukamoto S, Mavrogenis AF, Tanaka Y, Kido A, Kawaguchi M, Errani C.
    Orthopedics; 2021 Jun 05; 44(6):326-332. PubMed ID: 34618637
    [Abstract] [Full Text] [Related]

  • 35. A randomized phase III trial of denosumab before curettage for giant cell tumor of bone: Japan Clinical Oncology Group Study JCOG1610.
    Urakawa H, Mizusawa J, Tanaka K, Eba J, Hiraga H, Kawai A, Nishida Y, Hosaka M, Iwamoto Y, Fukuda H, Ozaki T.
    Jpn J Clin Oncol; 2019 Apr 01; 49(4):379-382. PubMed ID: 30796832
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Giant cell tumor of the bone: aggressive case initially treated with denosumab and intralesional surgery.
    von Borstel D, A Taguibao R, A Strle N, E Burns J.
    Skeletal Radiol; 2017 Apr 01; 46(4):571-578. PubMed ID: 28188337
    [Abstract] [Full Text] [Related]

  • 38. Malignancy in giant cell tumor of bone: analysis of an open-label phase 2 study of denosumab.
    Palmerini E, Seeger LL, Gambarotti M, Righi A, Reichardt P, Bukata S, Blay JY, Dai T, Jandial D, Picci P.
    BMC Cancer; 2021 Jan 22; 21(1):89. PubMed ID: 33482769
    [Abstract] [Full Text] [Related]

  • 39. Giant Cell Tumor of Bone of the First Rib Successfully Treated with Combined Preoperative Denosumab Therapy and Surgery via a Transmanubrial Approach.
    Matsunobu T, Maekawa A, Nabeshima A, Sakamoto A, Tamura K, Odate S, Iwamoto Y.
    Am J Case Rep; 2021 Jun 01; 22():e931796. PubMed ID: 34059614
    [Abstract] [Full Text] [Related]

  • 40. Giant cell tumor of the thoracic spine completely removed by total spondylectomy after neoadjuvant denosumab therapy.
    Yonezawa N, Murakami H, Kato S, Takeuchi A, Tsuchiya H.
    Eur Spine J; 2017 May 01; 26(Suppl 1):236-242. PubMed ID: 28396950
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.